Good day for $HIMS (-1.22%) ! The FDA Peptide Panel approves BPC-157.
Thats an important step for $HIMS (-1.22%) to legally offer highly demanded compounded peptides, unlocking a massive new recurring revenue stream. BPC-157 is incredibly popular in the wellness and fitness communities for recovery, and this advisory vote removes a big regulatory hurdle for $HIMS (-1.22%) . Its going to be interesting to see if other Peptides will also get approved in the process.